Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2006, 42(8): 533
ISSN 1699-3993
e-ISSN 1699-4019
Copyright 2006 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2006.42.8.996569
 
 
Anidulafungin: A new echinocandin for the treatment of fungal infections
Cohen-Wolkowiez, M., Benjamin , D.B. Jr., Steinbach , W.J., Smith, P.B.
 
 
Immunocompromised hosts are at increased risk for invasive fungal infections. Over the last five decades, the mainstay of therapy against systemic mycoses has revolved around amphotericin B deoxycholate. Unfortunately, this drug has substantial toxicities, and agents such as fluconazole were developed as an alternative to treat and prevent these invasive infections. Due to widespread use, fluconazole-resistant organisms have emerged; therefore, new agents with improved safety, efficacy and tolerability have now become desirable. The echinocandins are a new class of antifungal agents with novel activity against the fungal cell wall. In February 2006, the U.S. Food and Drug Administration approved the echinocandin anidulafungin for the treatment of patients with candidemia, peritonitis, intra-abdominal abscesses and esophageal candidiasis.


Full Text: HTMLPDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences